

First Annual Georgia Cancer Center Retreat Augusta Marriott at the Convention Center

Friday, June 28, 2024

7:30AM - 4:30PM

7:30 - 8:00	Registration and Breakfast
8:00 - 8:15	Welcome
	David Hess, MD, EVP, Medical Affairs and Dean, Medical College of Georgia
8:15 - 9:30	Keynote Lecture
	Raymond N. DuBois, MD, PhD, Director of MUSC Hollings Cancer Center
9:30 - 10:00	Path Towards NCI Designation
	Jorge Cortes, MD, Director, Georgia Cancer Center
10:00 - 10:30	BREAK
10:30 - 11:30	Molecular Oncology and Biomarkers Research Program
10:30-10:45	Molecular Oncology and Biomarker Research Program, Present and Future
	Nahid Mivechi, PhD, Professor of Radiation Oncology and Program Leader for Molecular Oncology
	and Biomarker Research Program
10:50-11:05	Kidney, Bladder and Prostate Research Program at Georgia Cancer Center
11:10-11:25	Balakrishna Lokeshwar, PhD, Professor, Georgia Cancer Center Blockade of TREM1 signaling as a novel therapeutic approach for cancer treatment
11:10-11:25	Anatolij Horuzsko, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology
	Anatony noruzsko, MD, Fild, Frolessor of Medicine, Diochemistry and Molecular Diology
11:30 - 12:00	State of the Research in Georgia Cancer Center
11.50 12.00	State of the Research in Georgia Gancer Genter
	Balveen Kaur, PhD, Professor of Pathology and Associate Director, Georgia Cancer Center
	Balveen Kaur, PhD, Professor of Pathology and Associate Director, Georgia Cancer Center
12:00 - 2:00	Balveen Kaur, PhD, Professor of Pathology and Associate Director, Georgia Cancer Center Lunch and Posters
12:00 - 2:00 2:00 - 3:00	
	Lunch and Posters
2:00 - 3:00	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation,
2:00 - 3:00 2:00 - 2:15	Lunch and Posters Cancer Immunology Research Program <i>Cancer Immunology Program Overview</i> Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC
2:00 - 3:00	Lunch and Posters Cancer Immunology Research Program <i>Cancer Immunology Program Overview</i> Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC <i>The CD73-ADO immune checkpoint during tumor progression and therapy</i>
2:00 - 3:00 2:00 - 2:15 2:15-2:30	Lunch and Posters         Cancer Immunology Research Program         Cancer Immunology Program Overview         Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC         The CD73-ADO immune checkpoint during tumor progression and therapy         Yan Cui, PhD, Professor of Biochemistry and Molecular Biology
2:00 - 3:00 2:00 - 2:15	Lunch and Posters Cancer Immunology Research Program <i>Cancer Immunology Program Overview</i> Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC <i>The CD73-ADO immune checkpoint during tumor progression and therapy</i> Yan Cui, PhD, Professor of Biochemistry and Molecular Biology <i>Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity</i>
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45	Lunch and PostersCancer Immunology Research Program Cancer Immunology Program OverviewCatherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCCThe CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular BiologyTargeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology
2:00 - 3:00 2:00 - 2:15 2:15-2:30	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC The CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular Biology Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology CAR T cell affinity: Moderate is better
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45	Lunch and PostersCancer Immunology Research Program Cancer Immunology Program OverviewCatherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCCThe CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular BiologyTargeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45 2:45-3:00	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC The CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular Biology Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology CAR T cell affinity: Moderate is better Yukai He, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC The CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular Biology Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology CAR T cell affinity: Moderate is better Yukai He, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology State of Clinical Research
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45 2:45-3:00	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC The CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular Biology Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology CAR T cell affinity: Moderate is better Yukai He, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45 2:45-3:00	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC The CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular Biology Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology CAR T cell affinity: Moderate is better Yukai He, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology State of Clinical Research
2:00 - 3:00 2:00 - 2:15 2:15-2:30 2:30-2:45 2:45-3:00 3:00 - 3:30	Lunch and Posters Cancer Immunology Research Program Cancer Immunology Program Overview Catherine "Lynn" Hedrick, PhD, Professor of Medicine, Head of Cancer Immunology, Inflammation, and Tolerance (CIIT) Division of GCC The CD73-ADO immune checkpoint during tumor progression and therapy Yan Cui, PhD, Professor of Biochemistry and Molecular Biology Targeting the RAS-MAPK signaling pathway to unleash antitumor immunity Gang Zhou, PhD, Professor of Medicine, Biochemistry and Molecular Biology CAR T cell affinity: Moderate is better Yukai He, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology State of Clinical Research Vamsi Kota, MD, Professor of Medicine, Director of Bone Marrow & Stem Cell Transplant Program